Skip to main content
. 2012 Mar 7;205(8):1294–1304. doi: 10.1093/infdis/jis107

Table 3.

Trial B Vaccine Responders

CMV Peptide Vaccine/Dose CMV-Seropositive CMV-Seropositive<0.2% CMV-Seronegative
PADRE-CMV, 0.5 mg 0/2 1/2 0/2
PADRE-CMV, 2.5 mg None 1/4 0/2
PADRE-CMV, 10 mg 0/2 1/4 None
Tet-CMV, 0.5 mg 0/3 2/3 None
Tet-CMV, 2.5 mg 0/2 3/4 None

For each cohort of 6 volunteers: numerators represent vaccine responders (denominators indicate total vaccinated).

Abbreviation: CMV, cytomegalovirus; CMV-seropositive<0.2%, CMV-seropositive subjects whose baseline pp65495-503 tetramer levels were minimal to low (<0.2%).